- Home
- DCOMP vs IOVA Comparison
DCOMP vs IOVA Comparison
Compare DCOMP & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOMP
- IOVA
- Stock Information
- Founded
- DCOMP N/A
- IOVA 2007
- Country
- DCOMP United States
- IOVA United States
- Employees
- DCOMP 887
- IOVA N/A
- Industry
- DCOMP Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCOMP Finance
- IOVA Health Care
- Exchange
- DCOMP Nasdaq
- IOVA Nasdaq
- Market Cap
- DCOMP N/A
- IOVA 1.0B
- IPO Year
- DCOMP N/A
- IOVA N/A
- Fundamental
- Price
- DCOMP $18.89
- IOVA $3.61
- Analyst Decision
- DCOMP
- IOVA Strong Buy
- Analyst Count
- DCOMP 0
- IOVA 9
- Target Price
- DCOMP N/A
- IOVA $18.22
- AVG Volume (30 Days)
- DCOMP N/A
- IOVA 10.0M
- Earning Date
- DCOMP N/A
- IOVA 05-08-2025
- Dividend Yield
- DCOMP N/A
- IOVA N/A
- EPS Growth
- DCOMP N/A
- IOVA N/A
- EPS
- DCOMP N/A
- IOVA N/A
- Revenue
- DCOMP N/A
- IOVA $164,070,000.00
- Revenue This Year
- DCOMP N/A
- IOVA $182.20
- Revenue Next Year
- DCOMP N/A
- IOVA $62.10
- P/E Ratio
- DCOMP N/A
- IOVA N/A
- Revenue Growth
- DCOMP N/A
- IOVA 13698.99
- 52 Week Low
- DCOMP N/A
- IOVA $2.70
- 52 Week High
- DCOMP N/A
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- DCOMP 50.89
- IOVA 54.38
- Support Level
- DCOMP $18.37
- IOVA $2.89
- Resistance Level
- DCOMP $19.19
- IOVA $3.43
- Average True Range (ATR)
- DCOMP 0.79
- IOVA 0.30
- MACD
- DCOMP 0.05
- IOVA 0.10
- Stochastic Oscillator
- DCOMP 79.31
- IOVA 95.60
About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.